Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 13/20 | 0.73 |
| ▸ | KCNQ2 | O43526 | 13/20 | 0.73 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703106 | 0.86 | KCNQ3 (0.58) | KCNQ3KCNQ2ALDH1A1MAPTHTT | |
| SCHEMBL3705354 | 0.85 | KCNQ3 (0.53) | KCNQ3KCNQ2EPHX2ALDH1A1MAPT | |
| SCHEMBL3707698 | 0.83 | KCNQ3 (0.69) | KCNQ3KCNQ2EPHX2PDE2A | |
| SCHEMBL3707697 | 0.83 | KCNQ3 (0.69) | KCNQ3KCNQ2EPHX2PDE2A | |
| SCHEMBL3710588 | 0.81 | KCNQ3 (0.69) | KCNQ3KCNQ2ALDH1A1 | |
| SCHEMBL3698128 | 0.80 | KCNQ3 (1.00) | KCNQ3KCNQ2ALDH1A1HTTPDE2A | |
| SCHEMBL3703662 | 0.79 | KCNQ3 (1.00) | KCNQ3KCNQ2RAB9APDE2ATDP1 | |
| SCHEMBL3704451 | 0.78 | KCNQ3 (0.74) | KCNQ3KCNQ2ALDH1A1MAPTRAB9A | |
| SCHEMBL3705767 | 0.77 | ALDH1A1 (0.45) | KCNQ3KCNQ2ALDH1A1MAPTHTT | |
| SCHEMBL3712462 | 0.77 | KCNQ3 (0.72) | KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609669-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | claimed |
| US-20120122888-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | claimed |
| US-8609669-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20120122888-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122888-A1 | Potassium Channel Modulators | KCNQ1, KCNQ2, KCNJ2 | KCNQ3 4/4885KCNQ2 2/4885EPHX2 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.